Grants & Support

Non-Dilutive and other support to date

JSK Therapeutics™ has been evaluated by many professionals performing due diligence and the results have been extremely favorable*.

National Cancer Institute Fast SBIR I/II Grant
$2,000,000

Kickstart seed investment
$325,000

Angel Investors
$100,000

Utah Center of Excellence Grant
$100,000

Cephalon
$100,000

National Cancer Institute RO1/ARRA Grant (Shami Lab)
$2,000,000

Investment Syndicate (first milestone achieved)
$5,700,000

TOTAL SUPPORT:
$10,300,000

* (The National Institutes of Health reviews ~40,000 applications every year, of which ~5,000 are industry-oriented submissions. Each application is peer reviewed by a select group of specialized researchers, senior academics, and experienced industry leaders. Reviewers provide a numerical value for five discrete review criteria summed as a single score, as well as a detailed explanation of the strengths and weaknesses of each parameter. The result is a quantitative, uniform, and comparable sliding scale of application submissions from the most worthy to the least and non-dilutive funding is thus awarded.)